rheumatoid arthritis

Latest Headlines

Latest Headlines

Myriad/Crescendo's rheumatoid arthritis test shows viability in new trial

Myriad Genetics paid $270 million for Crescendo Bioscience in February, and now a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity.

Inova picks up rheumatoid arthritis biomarkers from Dutch university

Inova Diagnostics once again has its sights on rheumatoid arthritis-detecting technology, this week acquiring a novel platform developed at Hasselt University designed to identify autoantibody biomarkers for the debilitating condition.

Booming Regeneron adds to R&D footprint in NY

With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space.

Top 10 rheumatoid arthritis drugs 2013

Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...

J&J's Simponi Aria approved for RA as it heads for blockbuster stratosphere

The FDA has approved Simponi in combination with methotrexate to treat moderately to severely active rheumatoid arthritis. The company points out that an estimated 1.3 million Americans and more than 23.5 million people worldwide suffer from RA. 

Crescendo Bioscience achieves Medicare coverage for RA Dx

Crescendo Bioscience won Medicare coverage for its rheumatoid arthritis molecular diagnostic, a major milestone and pivotal move in its bid to expand the test's market reach.

Cheaper generic combo found as effective in RA as blockbuster Enbrel

Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.

Humira carries AbbVie in its first quarter as standalone company

AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.

Pfizer appealing CHMP ruling on RA treatment Xeljanz

Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.

Cipla steamrolls into Enbrel market with biosimilar of Amgen drug

While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid arthritis blockbuster Enbrel, which it will sell in the subcontinent at a 30% discount.